Browse the evidence

GLP-1 receptor agonists may provide direct anti-inflammatory and disease-modifying benefits to osteoarthritic joints, independent of weight loss, by reducing pro-inflammatory cytokines and protecting chondrocytes.

Beyond helping you lose weight, GLP-1 medications might directly protect your knee joints from wear and tear. Research suggests these drugs can reduce inflammation within the joint itself and slow down cartilage loss, even independent of weight changes. This means you might experience less pain and slower progression of osteoarthritis, making these drugs a potentially dual-purpose treatment for both obesity and joint health.

Oral superabsorbent hydrogel (OSH) administration prevents diet-induced obesity and metabolic syndrome in mice by preserving gut barrier integrity and expanding Akkermansia muciniphila.

This research suggests that a specific type of hydrogel, when taken with meals, may help prevent weight gain and metabolic issues by protecting the gut lining and encouraging the growth of beneficial bacteria (A. muciniphila). While promising in mice, this is not yet a proven human therapy. Focus on proven methods like diet and exercise for now.

OSH administration improves metabolic parameters, including glucose tolerance and insulin sensitivity, by increasing GLP-1 levels and protecting the intestinal barrier.

This study indicates that OSH may help regulate blood sugar and insulin levels in mice by boosting GLP-1. This is a potential benefit for metabolic health, but more research is needed to see if it applies to humans.

OSH administration expands Akkermansia muciniphila abundance in the gut microbiota, which is associated with improved metabolic health.

This study shows that OSH can increase the levels of Akkermansia muciniphila, a bacterium linked to better metabolic health, in mice. This is a promising area of research, but it is not yet a proven strategy for humans.

Semaglutide use is associated with acute kidney injury (AKI), specifically acute interstitial nephritis (AIN) and podocytopathies (FSGS/MCD), particularly in patients with pre-existing chronic kidney disease (CKD) or advanced age.

If you are taking semaglutide and notice swelling, changes in urination, or fatigue, report it to your doctor immediately, especially if you have existing kidney disease. Most cases of kidney injury from semaglutide are reversible if the drug is stopped early and treated with steroids.

Long-acting GLP-1 receptor agonist (Ex-4)2-Fc promotes adipose tissue browning and thermogenesis in high-fat diet mice by enriching gut Lactobacillus reuteri and reducing serum ceramide levels via upregulation of alkaline ceramidase 2 (Acer2).

This research suggests that GLP-1 agonists do more than just suppress appetite; they actively change how fat tissue works by promoting 'browning' (heat production) and improving lipid metabolism. This effect is linked to changes in gut bacteria (specifically Lactobacillus reuteri) and the reduction of harmful lipids called ceramides. For individuals considering GLP-1 therapy, this highlights that the drug works through complex biological pathways beyond just eating less, potentially offering metabolic benefits even at lower doses when combined with healthy gut flora.

Combining GLP-1 receptor agonists with myostatin or activin type II receptor inhibitors (e.g., bimagrumab, trevogrumab, garetosmab) preserves or increases lean mass while enhancing fat loss, addressing the risk of sarcopenia and metabolic slowdown associated with standard AOM therapy.

Current GLP-1 therapies can lead to muscle loss, which may hinder long-term weight maintenance. Emerging combination therapies that pair GLP-1 agonists with muscle-preserving antibodies (like bimagrumab or myostatin inhibitors) show promise in preclinical models for doubling fat loss while increasing lean mass. Patients should discuss these emerging options with their providers, especially if they are concerned about muscle loss.

Weight regain after discontinuation of GLP-1-based AOMs is an inherent feature of current pharmacological strategies, but future interventions such as gene therapy (GLP-1PGTx) or gradual dose-tapering may mitigate this by sustaining hormonal signals or allowing hormonal adaptation.

Stopping GLP-1 medications currently leads to weight regain for most people due to hormonal adaptations. While lifestyle changes help, they may not be enough to counteract these hormonal shifts. Future treatments, such as gene therapy or careful dose-tapering, aim to sustain weight loss after stopping, but these are not yet standard care. Patients should plan for long-term management strategies with their providers.

Combined GIPR/GLP1R agonism lowers plasma triglyceride levels by increasing VLDL turnover (reduced hepatic VLDL-TG production and increased uptake by adipose tissue and liver).

Dual GIP/GLP-1 agonism improves lipid profiles by accelerating the clearance of triglyceride-rich lipoproteins (VLDL). This suggests that patients on these therapies may see significant improvements in triglyceride levels, which is a key risk factor for cardiovascular disease.

Combined GIPR/GLP1R agonism reduces systemic low-grade inflammation, evidenced by lower hepatic inflammatory markers and circulating adhesion molecules (ICAM-1, VCAM-1).

Dual GIP/GLP-1 therapy may help reduce chronic, low-grade inflammation associated with obesity and cardiovascular risk. This anti-inflammatory effect is part of the mechanism by which these drugs may protect blood vessels.

GLP-1 receptor agonists (GLP-1RAs) exert neuroprotective effects in neurodegenerative diseases (Alzheimer's, Parkinson's, Multiple Sclerosis) by modulating synaptic plasticity, reducing neuroinflammation, and promoting neurogenesis, although clinical trial outcomes remain variable.

GLP-1 drugs like semaglutide and liraglutide show promise in protecting brain cells and slowing cognitive/motor decline in diseases like Alzheimer's and Parkinson's, based on strong lab studies. However, human trials have been mixed, likely due to how patients are chosen and how trials are run. If you have a neurodegenerative condition, discuss with your doctor whether the potential brain benefits outweigh the risk of stomach side effects, especially if you are frail or elderly.

Novel GLP-1 receptor agonists (e.g., NLY01, tirzepatide) are being developed to enhance central nervous system penetration and efficacy, with some showing specific benefits in younger patient subgroups.

Newer GLP-1 drugs like NLY01 and tirzepatide are being designed to work better in the brain. Early results suggest they might help younger patients more than older ones. If you are interested in these treatments, ask your doctor about the latest clinical trials and whether a newer agent might be suitable for your specific condition and age.

Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a statistically significant increase in the dispensing of antidepressants, suggesting a potential adverse effect on mood or mental health.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Trulicity), be aware that there is a statistically higher chance you might be prescribed an antidepressant. This does not mean everyone will experience mood issues, but it is a known risk signal. Monitor your mental health closely, especially if you have a history of depression, and discuss any mood changes with your doctor immediately.

AMPK activation suppresses leptin secretion in adipocytes independently of adipogenesis and adipocyte maturity, challenging the view that AMPK's primary benefit is promoting adipose expansion.

While exercise and certain drugs activate AMPK to help store fat healthily, this research highlights that AMPK also directly reduces leptin, a hormone that tells your brain you're full. In obesity, high leptin levels cause resistance. By suppressing leptin secretion, AMPK activation might help restore the body's natural ability to feel full, offering a pathway to treat leptin resistance without just focusing on fat storage.

The Elipse swallowable intragastric balloon does not produce clinically significant weight loss or diabetes control in patients with obesity class 1-2 and type 2 diabetes when used in a real-world setting with standard nutritional follow-up.

If you have obesity and type 2 diabetes, this specific swallowable balloon is not a reliable standalone solution for significant weight loss in a standard healthcare setting. It resulted in only ~4% weight loss at 16 weeks, which is minimal compared to surgical options. It may be considered only if you strictly adhere to intensive dietary counseling and accept modest results, but it is not a substitute for more effective interventions.

Semaglutide is associated with a statistically significant signal of disproportionate reporting for depressive disorders in real-world pharmacovigilance data, whereas liraglutide and tirzepatide show no such signal.

If you are taking semaglutide, be aware that real-world data shows a higher reporting rate of depression compared to other GLP-1RAs like liraglutide or tirzepatide. This does not mean the drug definitely causes depression, but it suggests you should monitor your mood, especially if you are female. Discuss any mood changes with your doctor, as they may consider drug-specific monitoring.

Long-term use of GLP-1 receptor agonists (specifically liraglutide, dulaglutide, and exenatide) is associated with an increased risk of thyroid tumors, including C-cell hyperplasia and medullary thyroid carcinoma, primarily through the stimulation of GLP-1 receptors on thyroid C cells leading to calcitonin gene expression and cellular hyperplasia.

If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Victoza), your doctor should monitor your thyroid health, specifically checking calcitonin levels and potentially performing ultrasounds if you have symptoms or risk factors. This is because these drugs stimulate thyroid C-cells, which can lead to hyperplasia in animal models. While human risk is debated, caution is advised, especially if you have a family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 (MEN2).

GLP-1 receptor agonists may increase the risk of acute pancreatitis and pancreatic cancer, although meta-analyses have sometimes excluded this risk, and the evidence remains inconclusive with conflicting study results.

Be aware of symptoms of pancreatitis (severe abdominal pain, nausea, vomiting) while on GLP-1 medications. While the absolute risk is debated, it is a known potential side effect. Report any persistent abdominal pain to your doctor immediately.

Chronic inflammation in RA and PsA contributes to increased CVD risk, but the prevalence of Metabolic Syndrome (MetS) alone may not fully account for this risk, particularly in RA where MetS prevalence is similar to the general population.

Having RA or PsA increases your CVD risk beyond just traditional factors like blood pressure or cholesterol. This is partly due to chronic inflammation. Therefore, comprehensive care should address both metabolic risks (like MetS components) and inflammatory control, not just one or the other.

GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide) are associated with statistically significant signals for otolaryngologic adverse events, specifically GERD, Medullary Thyroid Carcinoma (MTC), and Papillary Thyroid Carcinoma (PTC), across all approved drugs.

If you take a GLP-1 drug like Ozempic or Wegovy, be aware that reports of acid reflux (GERD) and thyroid issues (MTC/PTC) are significantly higher than background noise in the FDA database. You should discuss these risks with your doctor and monitor for symptoms like persistent heartburn or neck lumps, but do not stop medication without medical advice.

Semaglutide and Liraglutide show significant signals for specific otolaryngologic adverse events including anosmia, dysgeusia, Bell's palsy, and tinnitus, which are not as strongly or consistently reported with other GLP-1 RAs.

If you take Semaglutide or Liraglutide and experience loss of smell, taste changes, ringing in the ears, or facial weakness (Bell's palsy), these are reported side effects. Inform your healthcare provider, as these may require management adjustments.

Patients with severe obesity perceive obesity as a disease due to a lack of control and addiction-like mechanisms, yet simultaneously maintain a belief in personal responsibility and self-blame, creating a barrier to accepting the disease label fully.

Understand that accepting obesity as a disease is complex for many patients. While biological factors like genetics and appetite dysregulation play a huge role, many patients still feel personal responsibility. This internal conflict can hinder treatment. Healthcare providers should address this shame and the 'addiction' narrative to help patients accept medical interventions without feeling they are failing morally.

Dietary supplementation with omega-3 polyunsaturated fatty acids (specifically DHA) attenuates nonalcoholic steatohepatitis (NASH) and fibrosis by suppressing betacellulin (BTC) expression, thereby inhibiting hepatic stellate cell proliferation and collagen production.

To support liver health and potentially reduce fibrosis risk, prioritize dietary sources of Docosahexaenoic Acid (DHA), a type of Omega-3 fatty acid. Research suggests DHA is particularly effective at suppressing betacellulin, a protein that drives liver scarring. While general Omega-3s help, DHA appears to have a stronger specific effect on this pathway. Consult a healthcare provider before making significant dietary changes, especially if you have existing liver conditions.

Dual activation of GPR10 and NPFF2 receptors by lipidated PrRP31 metabolites produces robust, long-acting weight loss in diet-induced obese mice, whereas GPR10-selective activation does not.

This research suggests that for obesity treatment, targeting both GPR10 and NPFF2 receptors simultaneously may be more effective than targeting GPR10 alone. The study used lipidated peptides in mice, showing significant weight loss. This is preclinical data and not a direct human treatment recommendation yet.